A trans-Tasman acquisition of a medical trial facility by a Kiwi firm is set to create Australasia’s largest independent, multi-phase clinical research business.
Case Study: With a dedicated start-up team and a streamlined ethics and regulatory process, NZCR consistently achieves some of the world’s fastest clinical trial approvals.
Case Study: NZCR is leading global innovation in gene editing, pioneering world-first studies like the in vivo CRISPR/Cas9 trial and positioning New Zealand as a premier destination for developing cutting-edge, tailored medicines.
NZCR are delighted to have played an important role in helping Jazz Pharmaceuticals achieve the U.S. FDA’s accelerated approval of Modeyso™, the first and only targeted systemic therapy for an ultra‑rare and devastating brain tumour affecting children and young adults.
NZCR is featured in a newly released global series by BBC StoryWorks, The Next Frontier, exploring how biotechnology is tackling some of the world’s most critical health and sustainability challenges.
In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share some big news for Christchurch!
In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share changes implemented that you have asked for.
NZCR's commitment to rigorous research and patient safety is reflected in the positive results emerging from several key studies. Here's a look at recent successes that underscore NZCR's dedication to advancing global health.
A drug involved in the FLAMINGO Auckland study has received Orphan Drug Designation from the FDA for the treatment of Cystic Fibrosis. This is a major step forward in the journey to develop new treatments for this challenging genetic condition.
